This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
HAIFA, Israel, Feb. 11, 2014 (GLOBE NEWSWIRE) --
Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has formed a Preeclampsia Steering Committee to advance its PLacental eXpanded (PLX) cell therapies for the treatment of preeclampsia.
"Preeclampsia is an important indication for our PLX-PAD cells. Based on the dire need for a treatment and the potential of our cell therapy in this indication, we have made it a key priority to enter clinical trials for preeclampsia in the near future," stated Pluristem Chairman and CEO Zami Aberman. "The caliber of medical and scientific thought leaders who have joined our Preeclampsia Steering Committee is a testament to the promise of our PLX cell therapy as a potential treatment for this disease."
Preeclampsia Steering Committee Member, Dr. Sibai, who was a moderator on the preeclampsia scientific forum, "Debate and Consensus: Preeclampsia Biomarkers in Clinical Practice, Are we ready?" at the Society for Maternal Fetal Medicine in New Orleans on Feb 5, 2014, commented, "For almost a thousand years, physicians have had no therapy to offer women with preeclampsia. A safe and effective therapy is needed to treat these women and prolong gestation. Pluristem's PLX cells are a unique potential therapy because they originate from the placenta, which plays a key role in preeclampsia."
Head Division of Obstetrics and Gynecology at Hadassah Medical Center
Head of the Israeli Association of Placental Study
The Preeclampsia Steering Committee will guide Pluristem's preeclampsia program including advising on various stages of clinical trials, from the design of the study protocol through processing patient feedback up to the final study report. Committee members have vast knowledge of preeclampsia and a commitment to finding a treatment.